HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CGS 26393

prodrug of CGS-26303; RN given for (S)-isomer

Also Known As:

2-biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid; CGS-26393

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - CGS 26393: 2
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - CGS 26393: 2

Experts

1.	Jeng, Arco Y: 2 articles (11/2010 - 08/2002)
2.	Chai, Chee-Yin: 1 article (11/2010)
3.	Chen, Ing-Jun: 1 article (11/2010)
4.	Chou, Shah-Hwa: 1 article (11/2010)
5.	Dai, Zen-Kong: 1 article (11/2010)
6.	Hsieh, Chong-Chao: 1 article (11/2010)
7.	Tan, Mian-Shin: 1 article (11/2010)
8.	Wu, Bin-Nan: 1 article (11/2010)
9.	Wu, Jiunn-Ren: 1 article (11/2010)
10.	Yeh, Jwu-Lai: 1 article (11/2010)

Related Diseases

1.	Vascular Remodeling 11/01/2010 - "We investigated the protective effects of an orally active, dual endothelin converting enzyme (ECE)/neutral endopeptidase (NEP) inhibitor/CGS 26393 on pulmonary vascular remodeling and pulmonary expressions of ET-1 and endothelial nitric oxide synthase (eNOS) during the development of PH secondary to cardiac dysfunction. "
2.	Intracranial Vasospasm 08/01/2002 - "The present study examined the effects of CGS 26393 on the prevention and reversal of cerebral vasospasm after SAH. " 08/01/2002 - "This study provides the first evidence that oral administration of an inhibitor of ECE-1, CGS 26393, is capable of preventing and reversing cerebral vasospasm following SAH. " 08/01/2002 - "Oral administration of CGS 26393 attenuated SAH-induced cerebral vasospasm in a dose-dependent manner in both the prevention and reversal groups. "

Related Drugs and Biologics

1.	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
2.	Neprilysin (Neutral Endopeptidase)
3.	Endothelin-Converting Enzymes

Related Therapies and Procedures

1.	Oral Administration